Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Venetoclax resistance in CLL

Arnon Kater • 14 Jun 2019
EHA 2019
Chronic Lymphocytic Leukemia Leukemia Ibrutinib Venetoclax

From the educational session, Arnon Kater, PhD, of University of Amsterdam, Amsterdam, Netherlands, discusses tumor resistance to venetoclax in chronic lymphocytic leukemia (CLL). Recorded at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Arnon Kater

2:28
GLOW trial updates: predicting outcomes using genomic aberrations and MRD status
Arnon Kater • 6 Oct 2023
1:46
Overcoming T-cell dysfunction
Arnon Kater • 6 Oct 2023
0:53
The future of CLL treatment
Arnon Kater • 6 Oct 2023
2:17
EPCORE CLL-1: epcoritamab in patients with R/R CLL & Richter's transformation
Arnon Kater • 6 Oct 2023

Related Videos

1:15
Comparing the efficacy of salvage therapies in adult B-ALL: a retrospective real-world study
Alex Rampotas • 16 Apr 2024
3:34
Total marrow and lymphoid irradiation plus cyclophosphamide & etoposide in poor-risk acute leukemias
Anthony Stein • 15 Apr 2024
2:24
Manipulating the gut microbiome to improve outcomes of alloSCT for hematological malignancies
Florent Malard • 11 Apr 2024
2:05
Investigating mutation order in AML using single-cell sequencing
Ravindra Majeti • 8 Apr 2024
The content of VJHemOnc is intended for healthcare professionals